SON.HO.UN.ADR 1/5 SF -05 (PHBA) - Net Assets
Based on the latest financial reports, SON.HO.UN.ADR 1/5 SF -05 (PHBA) has net assets worth €2.45 Billion EUR (≈ $2.86 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.51 Billion ≈ $6.44 Billion USD) and total liabilities (€3.06 Billion ≈ $3.58 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore PHBA cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.45 Billion |
| % of Total Assets | 44.43% |
| Annual Growth Rate | 3.34% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.63 |
SON.HO.UN.ADR 1/5 SF -05 - Net Assets Trend (2022–2025)
This chart illustrates how SON.HO.UN.ADR 1/5 SF -05's net assets have evolved over time, based on quarterly financial data. Also explore total assets of SON.HO.UN.ADR 1/5 SF -05 for the complete picture of this company's asset base.
Annual Net Assets for SON.HO.UN.ADR 1/5 SF -05 (2022–2025)
The table below shows the annual net assets of SON.HO.UN.ADR 1/5 SF -05 from 2022 to 2025. For live valuation and market cap data, see PHBA market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €2.68 Billion ≈ $3.14 Billion |
+7.76% |
| 2024-03-31 | €2.49 Billion ≈ $2.91 Billion |
+11.65% |
| 2023-03-31 | €2.23 Billion ≈ $2.61 Billion |
-8.28% |
| 2022-03-31 | €2.43 Billion ≈ $2.84 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SON.HO.UN.ADR 1/5 SF -05's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.67 Billion | 100.10% |
| Total Equity | €2.66 Billion | 100.00% |
SON.HO.UN.ADR 1/5 SF -05 Competitors by Market Cap
The table below lists competitors of SON.HO.UN.ADR 1/5 SF -05 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sinopac Financial Holdings Co Ltd
TW:2890
|
$12.25 Billion |
|
HF Sinclair Corp
NYSE:DINO
|
$12.27 Billion |
|
TAISEI CORP. ADR/ 1/4
F:TKK
|
$12.29 Billion |
|
James Hardie Industries Plc
AU:JHX
|
$12.29 Billion |
|
DT Midstream Inc
NYSE:DTM
|
$12.24 Billion |
|
Invesco Plc
NYSE:IVZ
|
$12.23 Billion |
|
Medpace Holdings Inc
NASDAQ:MEDP
|
$12.22 Billion |
|
TELE2 AB UNSP.ADR/1/2 B
F:NCY
|
$12.21 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SON.HO.UN.ADR 1/5 SF -05's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,470,400,000 to 2,664,600,000, a change of 194,200,000 (7.9%).
- Net income of 540,500,000 contributed positively to equity growth.
- Dividend payments of 256,200,000 reduced retained earnings.
- Share repurchases of 67,300,000 reduced equity.
- New share issuances of 29,200,000 increased equity.
- Other factors decreased equity by 52,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €540.50 Million | +20.28% |
| Dividends Paid | €256.20 Million | -9.61% |
| Share Repurchases | €67.30 Million | -2.53% |
| Share Issuances | €29.20 Million | +1.1% |
| Other Changes | €-52.00 Million | -1.95% |
| Total Change | €- | 7.86% |
Book Value vs Market Value Analysis
This analysis compares SON.HO.UN.ADR 1/5 SF -05's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.85x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.96x to 0.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | €39.46 | €37.80 | x |
| 2023-03-31 | €37.12 | €37.80 | x |
| 2024-03-31 | €41.44 | €37.80 | x |
| 2025-03-31 | €44.70 | €37.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SON.HO.UN.ADR 1/5 SF -05 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.28%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.98%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 2.22x
- Recent ROE (20.28%) is below the historical average (25.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 26.92% | 19.29% | 0.60x | 2.32x | €407.95 Million |
| 2023 | 29.27% | 17.32% | 0.67x | 2.51x | €426.26 Million |
| 2024 | 24.33% | 16.57% | 0.63x | 2.34x | €353.96 Million |
| 2025 | 20.28% | 13.98% | 0.65x | 2.22x | €274.04 Million |
Industry Comparison
This section compares SON.HO.UN.ADR 1/5 SF -05's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $37,411,546,005
- Average return on equity (ROE) among peers: -877.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SON.HO.UN.ADR 1/5 SF -05 (PHBA) | €2.45 Billion | 26.92% | 1.25x | $12.25 Billion |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.50 Billion | 7.19% | 0.43x | $146.67K |
| BIORETEC OY (0TN) | $9.74 Million | -47.38% | 0.18x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $349.05 Billion | 12.63% | 0.39x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $703.81 Million | 25.76% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $76.93K | -8590.94% | 35.29x | $28.30 Million |
| Medtronic PLC (2M6) | $1.75 Billion | 30.35% | 0.38x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $2.64 Billion | -15.46% | 0.26x | $391.36 Million |
| AVITA Medical Inc (51KB) | $20.86 Million | -118.03% | 0.23x | $172.49 Million |
| BRAINCOOL AB (5YL) | $111.74 Million | -54.84% | 0.19x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.33 Billion | -20.20% | 0.10x | $107.57 Million |
About SON.HO.UN.ADR 1/5 SF -05
Sonova Holding AG manufactures and sells hearing care solutions for children and adults in Switzerland, the United States, rest of the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The Hearing Instruments segment engages in the design, development, manufacture, distribution, and service of hea… Read more